KR101359943B1 - Ｈｐｖ 16과 ｈｐｖ 18 및 적어도 ｈｐｖ 31, 45 또는 52로부터 선택된 또 다른 ｈｐｖ 유형에 대한 백신 - Google Patents

Ｈｐｖ 16과 ｈｐｖ 18 및 적어도 ｈｐｖ 31, 45 또는 52로부터 선택된 또 다른 ｈｐｖ 유형에 대한 백신 Download PDF

Info

Publication number
KR101359943B1
KR101359943B1 KR1020127027786A KR20127027786A KR101359943B1 KR 101359943 B1 KR101359943 B1 KR 101359943B1 KR 1020127027786 A KR1020127027786 A KR 1020127027786A KR 20127027786 A KR20127027786 A KR 20127027786A KR 101359943 B1 KR101359943 B1 KR 101359943B1
Authority
KR
South Korea
Prior art keywords
hpv
vlps
vaccine
types
vlp
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
KR1020127027786A
Other languages
English (en)
Korean (ko)
Other versions
KR20120123617A (ko
Inventor
세르게 데브루스
마리-테레세 마틴
로버트 존 스티븐
진 스테펜느
마틴 안네 쎄실 웨텐도르프
Original Assignee
글락소스미스클라인 바이오로지칼즈 에스.에이.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US11/114,301 external-priority patent/US20050287161A1/en
Application filed by 글락소스미스클라인 바이오로지칼즈 에스.에이. filed Critical 글락소스미스클라인 바이오로지칼즈 에스.에이.
Priority claimed from PCT/EP2005/006461 external-priority patent/WO2005123125A1/en
Publication of KR20120123617A publication Critical patent/KR20120123617A/ko
Application granted granted Critical
Publication of KR101359943B1 publication Critical patent/KR101359943B1/ko
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/12—Keratolytics, e.g. wart or anti-corn preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Communicable Diseases (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
KR1020127027786A 2004-06-16 2005-06-14 Ｈｐｖ 16과 ｈｐｖ 18 및 적어도 ｈｐｖ 31, 45 또는 52로부터 선택된 또 다른 ｈｐｖ 유형에 대한 백신 Expired - Lifetime KR101359943B1 (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GBGB0413510.9A GB0413510D0 (en) 2004-06-16 2004-06-16 Vaccine
GB0413510.9 2004-06-16
US11/114,301 2005-04-26
US11/114,301 US20050287161A1 (en) 2002-12-20 2005-04-26 Vaccine
PCT/EP2005/006461 WO2005123125A1 (en) 2004-06-16 2005-06-14 Vaccine against hpv16 and hpv18 and at least another hpv type selected from hpv 31, 45 or 52

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020077001065A Division KR20070029254A (ko) 2004-06-16 2005-06-14 Ｈｐｖ 16과 ｈｐｖ 18 및 적어도 ｈｐｖ 31, 45 또는52로부터 선택된 또 다른 ｈｐｖ 유형에 대한 백신

Publications (2)

Publication Number Publication Date
KR20120123617A KR20120123617A (ko) 2012-11-08
KR101359943B1 true KR101359943B1 (ko) 2014-02-10

Family

ID=32750044

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020127027786A Expired - Lifetime KR101359943B1 (ko) 2004-06-16 2005-06-14 Ｈｐｖ 16과 ｈｐｖ 18 및 적어도 ｈｐｖ 31, 45 또는 52로부터 선택된 또 다른 ｈｐｖ 유형에 대한 백신

Country Status (15)

Country Link
JP (1) JP2012102132A (https=)
KR (1) KR101359943B1 (https=)
CN (1) CN1976718B (https=)
CY (1) CY1113830T1 (https=)
DK (1) DK1758609T3 (https=)
ES (1) ES2394448T3 (https=)
GB (1) GB0413510D0 (https=)
HR (1) HRP20120930T1 (https=)
HU (3) HUS1500059I1 (https=)
LT (1) LTC1758609I2 (https=)
NL (3) NL300774I1 (https=)
PT (1) PT1758609E (https=)
SI (1) SI1758609T1 (https=)
TW (1) TW200612983A (https=)
ZA (1) ZA200610057B (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010118424A2 (en) * 2009-04-10 2010-10-14 The Johns Hopkins University Papillomavirus-like particles (vlp) as broad spectrum human papillomavirus (hpv) vaccines
BR112013000912A2 (pt) * 2010-07-15 2016-05-17 British Columbia Cancer Agency composições de antígeno e7 de papilomavírus humano e usos dos mesmos
CN107188966B (zh) 2016-03-15 2020-03-31 中国医学科学院基础医学研究所 一种乳头瘤病毒嵌合蛋白及其用途
CN114539365B (zh) * 2020-11-26 2023-12-01 中国医学科学院基础医学研究所 一种改造的人乳头瘤病毒52型l1蛋白及其用途
CN114716561B (zh) 2021-01-04 2024-03-12 中国医学科学院基础医学研究所 一种人乳头瘤病毒31型嵌合蛋白及其用途
CN114716560B (zh) 2021-01-04 2024-02-02 中国医学科学院基础医学研究所 一种人乳头瘤病毒18型嵌合蛋白及其用途
CN119464385B (zh) * 2024-12-04 2026-04-07 华中科技大学同济医学院附属同济医院 Matv11重组腺病毒载体、应用、制备方法及hpv治疗性疫苗

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003077942A2 (en) * 2002-03-18 2003-09-25 Glaxosmithkline Biologicals Sa Virus-like particles of human papillomavirus

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9921146D0 (en) * 1999-09-07 1999-11-10 Smithkline Beecham Biolog Novel composition
GB9921147D0 (en) * 1999-09-07 1999-11-10 Smithkline Beecham Biolog Novel composition
GB0110431D0 (en) * 2001-04-27 2001-06-20 Glaxosmithkline Biolog Sa Novel compounds
GB0206359D0 (en) * 2002-03-18 2002-05-01 Glaxosmithkline Biolog Sa Viral antigens

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003077942A2 (en) * 2002-03-18 2003-09-25 Glaxosmithkline Biologicals Sa Virus-like particles of human papillomavirus

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
Journal of Virology, Vol. 76, No. 13, p6480-6486, 2002.07 *
Journal of Virology, Vol. 76, No. 13, p6480-6486, 2002.07*
The Journal of Infectious Diseases, Vol. 186, p737-742, epub. 2002.08.28. *
The Journal of Infectious Diseases, Vol. 186, p737-742, epub. 2002.08.28.*

Also Published As

Publication number Publication date
GB0413510D0 (en) 2004-07-21
HUS1500059I1 (hu) 2017-10-30
CY1113830T1 (el) 2016-06-22
NL300774I2 (https=) 2015-12-29
NL300773I2 (https=) 2015-12-29
LTC1758609I2 (lt) 2017-05-10
NL300773I1 (https=) 2015-12-29
DK1758609T3 (da) 2012-12-10
HUS1500060I1 (hu) 2017-10-30
ZA200610057B (en) 2008-02-27
HUS1500061I1 (hu) 2016-01-28
NL300774I1 (https=) 2015-12-29
KR20120123617A (ko) 2012-11-08
PT1758609E (pt) 2012-12-21
JP2012102132A (ja) 2012-05-31
SI1758609T1 (sl) 2013-01-31
NL300771I1 (https=) 2015-12-29
NL300771I2 (https=) 2015-12-29
CN1976718B (zh) 2012-10-10
HRP20120930T1 (hr) 2012-12-31
ES2394448T3 (es) 2013-01-31
CN1976718A (zh) 2007-06-06
TW200612983A (en) 2006-05-01

Similar Documents

Publication Publication Date Title
US20050287161A1 (en) Vaccine
JP2012102132A (ja) Ｈｐｖ１６およびｈｐｖ１８ならびにｈｐｖ３１、４５または５２から選ばれる少なくとも１つの別のｈｐｖ型に対するワクチン
EP1758609B1 (en) Vaccine against hpv16 and hpv18 and at least another hpv type selected from hpv 31, 45 or 52
US20090181052A1 (en) Vaccine
US7758866B2 (en) Vaccine against HPV16 and HPV18 and at least another HPV type selected from HPV 31, 45 or 52
US7858098B2 (en) Vaccine
CN100418577C (zh) Hpv-16和hpv-18l1vlp疫苗
CN101217976A (zh) 疫苗
CN101217975A (zh) 疫苗
KR20080005583A (ko) 백신
BRPI0610396A2 (pt) vacina de hpv multivalente, métodos para proteger um paciente contra a infecção, para prevenir ou reduzir a freqüênca de anormalidades citológicas em um paciente, para prevenir a formação de lesões cin histologicamente confirmadas e para fabricar a vacina, e, usos de uma composição, de uma vacina e de uma composição de vacina
BRPI0610032A2 (pt) uso de uma proteìna l1 do papilomavìrus humano ou fragmento imunogêico da mesma de um primeiro tipo de hpv, programa de vacinação para proteção contra a infecção e/ou doença por hiv, método para prevenção da infecção e/ou doença por hpv, composição de vacina, e, kit
HK1085378B (en) Use of hpv16 and hpv18 as vaccine against one or more of oncogenic hpv type 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, 68

Legal Events

Date Code Title Description
A107 Divisional application of patent
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20121024

Application number text: 1020077001065

Filing date: 20070116

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20121113

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20130208

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20131224

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20140203

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20140204

End annual number: 3

Start annual number: 1

PG1601 Publication of registration
A101 Application to extend term of patent right by permit
PA0101 Application to register extension of term of patent right by permit, etc.

Patent event date: 20160425

Patent event code: PA01011R01D

Comment text: Application to Register Extension of Term of Patent Right by Permit, etc.

FPAY Annual fee payment

Payment date: 20161229

Year of fee payment: 4

PR1001 Payment of annual fee

Payment date: 20161229

Start annual number: 4

End annual number: 4

FPAY Annual fee payment

Payment date: 20171228

Year of fee payment: 5

PR1001 Payment of annual fee

Payment date: 20171228

Start annual number: 5

End annual number: 5

FPAY Annual fee payment

Payment date: 20181227

Year of fee payment: 6

PR1001 Payment of annual fee

Payment date: 20181227

Start annual number: 6

End annual number: 6

FPAY Annual fee payment

Payment date: 20191227

Year of fee payment: 7

PR1001 Payment of annual fee

Payment date: 20191227

Start annual number: 7

End annual number: 7

FPAY Annual fee payment

Payment date: 20201224

Year of fee payment: 8

PR1001 Payment of annual fee

Payment date: 20201224

Start annual number: 8

End annual number: 8

FPAY Annual fee payment

Payment date: 20220125

Year of fee payment: 9

PR1001 Payment of annual fee

Payment date: 20220125

Start annual number: 9

End annual number: 9

PR1001 Payment of annual fee

Payment date: 20240130

Start annual number: 11

End annual number: 11

PR1001 Payment of annual fee

Payment date: 20241223

Start annual number: 12

End annual number: 12